NCT00004180 2023-06-26
Rosiglitazone in Treating Patients With Liposarcoma
Dana-Farber Cancer Institute
Phase 2 Completed
Dana-Farber Cancer Institute
Université de Sherbrooke
Bayer
University of Pittsburgh
GlaxoSmithKline
M.D. Anderson Cancer Center
Vanderbilt University
Genentech, Inc.
Exelixis
Massachusetts General Hospital
National Cancer Institute (NCI)